For more than three decades, the Prescription Drug User Fee Act (PDUFA) has helped make the United States the world leader in biopharmaceutical innovation. With PDUFA VII set to expire on September 30, 2027, Congress should move early to reauthorize PDUFA VIII and preserve one of the nation's most important competitive advantages.
PDUFA has transformed the FDA's human drug review program. Since its enactment in 1992, review timelines have fallen significantly, helping establish the United States as the first launch market for many innovative medicines. The program's success rests on a simple principle: providing FDA with the resources, expertise, and regulatory predictability needed to conduct timely, science-based reviews.
Maintaining that predictability is especially important as competition for biopharmaceutical investment intensifies globally. Delays or uncertainty in the review process affect more than regulatory timelines. They influence where companies conduct research, launch clinical trials, build manufacturing capacity, and bring new therapies to market.
PDUFA VIII includes several reforms that will help strengthen the review process. New opportunities for early engagement between FDA and sponsors are designed to address manufacturing and facility issues before they become barriers to approval. The agreement also incorporates proven regulatory science tools into standard FDA practice, reflecting years of successful experience with innovative approaches to drug development and review.
The Chamber also supports efforts to ensure the program remains forward-looking. As companies increasingly incorporate artificial intelligence and other advanced technologies into drug development, FDA should provide clear, risk-based guidance that encourages innovation while maintaining confidence in the regulatory process.
Equally important, PDUFA VIII recognizes the value of domestic investment. The agreement includes incentives that encourage early-stage clinical development in the United States, helping reinforce America's position as the premier destination for biopharmaceutical research and development.
Finally, strong financial stewardship remains essential. A well-resourced FDA review workforce is the foundation of the user fee program's success, and continued transparency and accountability will help ensure the agency can meet its commitments to patients and innovators alike.
PDUFA is more than an FDA funding mechanism. It is a critical component of the innovation ecosystem that helps ensure patients receive timely access to new medicines and that the United States remains the global leader in life sciences. Congress should act early to reauthorize PDUFA VIII and provide the certainty needed to sustain that success for years to come.
About the author
Grace Williams
Grace Williams is manager of Health Policy at the U.S. Chamber of Commerce, where she plays a key role in shaping and executing the Health Policy team’s advocacy priorities.
